BACKGROUND: Minimal residual disease is an important independent prognostic factor in childhood acute lymphoblastic leukemia. The classical detection methods such as multiparameter flow cytometry and real-time quantitative polymerase chain reaction analysis are expensive, time-consuming and complex, and require considerable technical expertise. DESIGN AND METHODS: We analyzed 229 consecutive children with acute lymphoblastic leukemia treated according to the GBTLI-99 protocol at three different Brazilian centers. Minimal residual disease was analyzed in bone marrow samples at diagnosis and on days 14 and 28 by conventional homo/heteroduplex polymerase chain reaction using a simplified approach with consensus primers for IG and TCR gene rearrangements. RESULTS: At least one marker was detected by polymerase chain reaction in 96.4% of the patients. By combining the minimal residual disease results obtained on days 14 and 28, three different prognostic groups were identified: minimal residual disease negative on days 14 and 28, positive on day 14/negative on day 28, and positive on both. Five-year event-free survival rates were 85%, 75.6%, and 27.8%, respectively (p<0.0001). The same pattern of stratification held true for the group of intensively treated children. When analyzed in other subgroups of patients such as those at standard and high risk at diagnosis, those with positive B-derived CD10, patients positive for the TEL/AML1 transcript, and patients in morphological remission on a day 28 marrow, the event-free survival rate was found to be significantly lower in patients with positive minimal residual disease on day 28. Multivariate analysis demonstrated that the detection of minimal residual disease on day 28 is the most significant prognostic factor. CONCLUSIONS: This simplified strategy for detection of minimal residual disease was feasible, reproducible, cheaper and simpler when compared with other methods, and allowed powerful discrimination between children with acute lymphoblastic leukemia with a good and poor outcome.
BACKGROUND: Minimal residual disease is an important independent prognostic factor in childhood acute lymphoblastic leukemia. The classical detection methods such as multiparameter flow cytometry and real-time quantitative polymerase chain reaction analysis are expensive, time-consuming and complex, and require considerable technical expertise. DESIGN AND METHODS: We analyzed 229 consecutive children with acute lymphoblastic leukemia treated according to the GBTLI-99 protocol at three different Brazilian centers. Minimal residual disease was analyzed in bone marrow samples at diagnosis and on days 14 and 28 by conventional homo/heteroduplex polymerase chain reaction using a simplified approach with consensus primers for IG and TCR gene rearrangements. RESULTS: At least one marker was detected by polymerase chain reaction in 96.4% of the patients. By combining the minimal residual disease results obtained on days 14 and 28, three different prognostic groups were identified: minimal residual disease negative on days 14 and 28, positive on day 14/negative on day 28, and positive on both. Five-year event-free survival rates were 85%, 75.6%, and 27.8%, respectively (p<0.0001). The same pattern of stratification held true for the group of intensively treated children. When analyzed in other subgroups of patients such as those at standard and high risk at diagnosis, those with positive B-derived CD10, patients positive for the TEL/AML1 transcript, and patients in morphological remission on a day 28 marrow, the event-free survival rate was found to be significantly lower in patients with positive minimal residual disease on day 28. Multivariate analysis demonstrated that the detection of minimal residual disease on day 28 is the most significant prognostic factor. CONCLUSIONS: This simplified strategy for detection of minimal residual disease was feasible, reproducible, cheaper and simpler when compared with other methods, and allowed powerful discrimination between children with acute lymphoblastic leukemia with a good and poor outcome.
Authors: T Flohr; A Schrauder; G Cazzaniga; R Panzer-Grümayer; V van der Velden; S Fischer; M Stanulla; G Basso; F K Niggli; B W Schäfer; R Sutton; R Koehler; M Zimmermann; M G Valsecchi; H Gadner; G Masera; M Schrappe; J J M van Dongen; A Biondi; C R Bartram Journal: Leukemia Date: 2008-01-31 Impact factor: 11.528
Authors: A Porwit-MacDonald; E Björklund; P Lucio; E G van Lochem; J Mazur; A Parreira; M W van den Beemd; E R van Wering; E Baars; G Gaipa; A Biondi; J Ciudad; J J van Dongen; J F San Miguel; A Orfao Journal: Leukemia Date: 2000-05 Impact factor: 11.528
Authors: J J van Dongen; E A Macintyre; J A Gabert; E Delabesse; V Rossi; G Saglio; E Gottardi; A Rambaldi; G Dotti; F Griesinger; A Parreira; P Gameiro; M G Diáz; M Malec; A W Langerak; J F San Miguel; A Biondi Journal: Leukemia Date: 1999-12 Impact factor: 11.528
Authors: Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta Journal: Blood Date: 2008-04-03 Impact factor: 22.113
Authors: Martin Stanulla; Gunnar Cario; Barbara Meissner; André Schrauder; Anja Möricke; Hansjörg Riehm; Martin Schrappe Journal: Blood Cells Mol Dis Date: 2007-05-25 Impact factor: 3.039
Authors: E Fronkova; E Mejstrikova; S Avigad; K W Chik; L Castillo; S Manor; L Reznickova; T Valova; K Zdrahalova; O Hrusak; Y Jabali; M Schrappe; V Conter; S Izraeli; C K Li; B Stark; J Stary; J Trka Journal: Leukemia Date: 2008-02-28 Impact factor: 11.528
Authors: Daniel Mazza Matos; Ana Cesarina Vitoriano de Oliveira; Maria de Nazaré Amaral Tomé; Carlos Alberto Scrideli Journal: Med Oncol Date: 2012-06-12 Impact factor: 3.064
Authors: Regina Maria Holanda de Mendonça; Marcela de Araújo; Carlos Emilio Levy; Joseane Morari; Rosângela A Silva; José Andres Yunes; Silvia Regina Brandalise Journal: Support Care Cancer Date: 2011-05-20 Impact factor: 3.603
Authors: Adriana Aparecida Siviero-Miachon; Angela Maria Spinola-Castro; Maria Lucia de Martino Lee; Antonio Ramos Calixto; Bruno Geloneze; Marise Lazaretti-Castro; Gil Guerra-Junior Journal: J Bone Miner Metab Date: 2015-12-11 Impact factor: 2.626
Authors: Kyung Nam Koh; Meerim Park; Bo Eun Kim; Ho Joon Im; Chan-Jeoung Park; Seongsoo Jang; Hyun Sook Chi; Jong Jin Seo Journal: Korean J Pediatr Date: 2010-11-30
Authors: Adriana Aparecida Siviero-Miachon; Angela Maria Spinola-Castro; Maria Lucia de Martino Lee; Carlos Manoel de Castro Monteiro; Antonio Carlos de Camargo Carvalho; Antonio Ramos Calixto; Bruno Geloneze; Gil Guerra-Junior Journal: Vasc Health Risk Manag Date: 2015-08-18
Authors: Hamilton L Gimenes-Teixeira; Antonio R Lucena-Araujo; Guilherme A Dos Santos; Dalila L Zanette; Priscila S Scheucher; Luciana C Oliveira; Leandro F Dalmazzo; Wilson A Silva-Júnior; Roberto P Falcão; Eduardo M Rego Journal: Exp Hematol Oncol Date: 2013-04-08
Authors: Lucila H Oliveira; Josiane L Schiavinato; Mariane S Fráguas; Antonio R Lucena-Araujo; Rodrigo Haddad; Amélia G Araújo; Leandro F Dalmazzo; Eduardo M Rego; Dimas T Covas; Marco A Zago; Rodrigo A Panepucci Journal: Cancer Sci Date: 2015-09-21 Impact factor: 6.716